Clinical data for patients for whom Pax5 isoforms have been analyzed
| Patient no. . | BM% at sample . | PCLI at sample, % . | Treatment . | No. of Pax5 isoforms in B cells . | Status at sample . | Other syndromes . | Comments . |
|---|---|---|---|---|---|---|---|
| Untreated patients | |||||||
| P17 | 26.8 | 1.6 | None | 5 (insert in PC) | Untreated | Enlarged prostate | Presented with compression fractures |
| P13 | 50 | 1 | None | 1 (no full-length) | Untreated | Hypertension | Presented in renal failure |
| P15 | 11 | 0.4 | None | 2 | Untreated | NA | Had PC radiated; no systemic therapy |
| P9 | 20 | 0.3 | None | 3 | Untreated | Breast cancer | NA |
| P16 | 20 | 0.2 | None | 2 | Untreated | Diabetes insipidus | 6-y h/o MGUS evolving to SMM |
| Asthma | |||||||
| P5 | 40 | 0 | None | 3 | Untreated | NA | NA |
| Treated patients | |||||||
| P14 | 20 | 0.9 | TD PBSCT | 3 | Remission | NA | Nonsecretory |
| P18 | 21.8 | 0.4 | RoRX, dex | 3 | Too early to evaluate | NA | Presented with T8 plasmacytoma |
| P11 | 58 | 0 | MP×2, dex | 7 | No response to initial RX | NA | NA |
| P6 | 31 | 0 | VAD | 3 | Remission | Hematuria, gout | CR after PBSCT and DC vaccines |
| P3 | 15 | 0 | VAD | 6 | Relapse | NA | Steady drop in IgA after DC vaccines |
| P7 | 0.40 | 0 | VAD VBMCP PBSCT | 3 | Remission | NA | CNS involvement at the time of bone marrow harvest |
| P12 | 8 | 0 | MP, dex | 3 | No response | Neuropathy | SMM, treated because of neuropathy |
| Cytoxan |
| Patient no. . | BM% at sample . | PCLI at sample, % . | Treatment . | No. of Pax5 isoforms in B cells . | Status at sample . | Other syndromes . | Comments . |
|---|---|---|---|---|---|---|---|
| Untreated patients | |||||||
| P17 | 26.8 | 1.6 | None | 5 (insert in PC) | Untreated | Enlarged prostate | Presented with compression fractures |
| P13 | 50 | 1 | None | 1 (no full-length) | Untreated | Hypertension | Presented in renal failure |
| P15 | 11 | 0.4 | None | 2 | Untreated | NA | Had PC radiated; no systemic therapy |
| P9 | 20 | 0.3 | None | 3 | Untreated | Breast cancer | NA |
| P16 | 20 | 0.2 | None | 2 | Untreated | Diabetes insipidus | 6-y h/o MGUS evolving to SMM |
| Asthma | |||||||
| P5 | 40 | 0 | None | 3 | Untreated | NA | NA |
| Treated patients | |||||||
| P14 | 20 | 0.9 | TD PBSCT | 3 | Remission | NA | Nonsecretory |
| P18 | 21.8 | 0.4 | RoRX, dex | 3 | Too early to evaluate | NA | Presented with T8 plasmacytoma |
| P11 | 58 | 0 | MP×2, dex | 7 | No response to initial RX | NA | NA |
| P6 | 31 | 0 | VAD | 3 | Remission | Hematuria, gout | CR after PBSCT and DC vaccines |
| P3 | 15 | 0 | VAD | 6 | Relapse | NA | Steady drop in IgA after DC vaccines |
| P7 | 0.40 | 0 | VAD VBMCP PBSCT | 3 | Remission | NA | CNS involvement at the time of bone marrow harvest |
| P12 | 8 | 0 | MP, dex | 3 | No response | Neuropathy | SMM, treated because of neuropathy |
| Cytoxan |
BM% indicates percentage of plasma cells at the time the sample was taken; PCLI, plasma cell labeling index at the time the sample was taken; P, MM patient; TD, thalidomide and dexamethasone; PBSCT, peripheral blood stem cell transplantation; dex, dexamethasone; MP×2, melphalan and prednisone (2 cycles); VAD, vincristine, adriamycin, and dexamethazone; DC, dendritic cells; VBMCP, vincristine, BCNU, melphalan, cyclophosphamide, and prednisone; BCNU, 1,3-bis(2-chlorethyl)-1-nitrosourea; RX, treatment; RoRx, radiation treatment; BM, bone marrow; SMM, smoldering multiple myeloma; PC, plasma cells; MGVS, monoclonal gammopathy of undetermined significance; DC, dendritic cell; CR, complete remission; CNS, central nervous system; and NA, not applicable.